Simple Summary Currently, the treatment for localized colon cancer consists of surgery and,
if the presence of residual cancer cells is suspected, chemotherapy following the surgery …

Background This article reviews the current knowledge on circulating tumor DNA (ctDNA) in
early stage colon cancer and ongoing trials on ctDNA-guided treatment in the adjuvant …

Liquid biopsies are the detection of molecular information in fluids from patients with cancer.
In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating …

Simple Summary Patients with colorectal cancer without distant metastases are often cured
by surgical tumor resection. Follow-up is needed because of the risk of disease recurrence …

Our understanding of the diagnostic and prognostic use of circulating tumor DNA (ctDNA) in
colorectal cancer (CRC) has broadly expanded over the past few years. The utilization of …

Emerging data have suggested that circulating tumor DNA (ctDNA) can be a reliable
biomarker for minimal residual disease (MRD) in CRC patients. Recent studies have shown …

BACKGROUND: The ability to detect circulating tumor DNA (ctDNA), a novel surrogate for
minimal residual disease (MRD) for patients with solid tumors, has significantly evolved over …

Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may
identify patients at the highest risk of recurrence and help inform adjuvant treatment …

An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

Simple Summary There is currently a lack of useful tests to detect microscopic residual
disease in patients who have undergone surgery to remove their bowel cancer. This inability …